Welcome to Integrated Oncology

Home Page - Slider

Working with Integrated Oncology
Oncology Testing
VistaSeq Hereditary Cancer Testing
For Patients
working with integrated oncology
Working with Integrated Oncology

More than 25 years of testing experience and expertise

Oncology Testing

Evolving personalize testing for you

vistaseq
VistaSeq Hereditary Cancer Testing

Because Knowledge is a Powerful Tool

for patients
For Patients

Dedicated to helping educate patients and inform the public about oncology diagnostic testing.

For Patients

Prepare for visits with your doctor or a genetic counselor by learning about testing.

Working with Integrated Oncology

Integrated Oncology Highlights

NEW test offering - OmniSeq Comprehensive next-gen molecular sequencing assay, identifying somatic variants in 144 genes.  Learn more.

NEW test offering - The OmniSeq Immune Report Card assay supports immunotherapy treatment decision making by providing comprehensive immune profiling from a single sample.  Learn more.

This test was recently FDA-approved as a complementary diagnostic assay that may help identify patients with locally advanced or metastatic urothelial carcinoma more likely to respond to treatment with TecentriqTM(atezolizumab).

Integrated Oncology now offers the FDA-approved cobas EGFR mutation test V2 in both FFPE tissue and plasma samples

This test was recently FDA-approved as a complementary diagnostic test to help physicians determine which patients may benefit most with OPDIVO® (nivolumab). 

This test was recently FDA approved as a companion diagnostic assay to aid in identifying metastatic NSCLC patients for treatment with KEYTRUDA® (pembrolizumab). 

Every patient comes from a different background with a unique personal and family history. Patients with a family history that is specific to one cancer type may receive more benefit from a focused hereditary panel test. Integrated Oncology offers several cancer panel options for a more targeted approach to testing.  Click here to view the press release.